European Medical Association

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

Retrieved on: 
Wednesday, March 13, 2024
Orphan drug, Growth, NESS, Nevoid basal-cell carcinoma syndrome, Disease, Patient, Research, European Medical Association, NDA, Acquisition, Prescription, EMA, Dermatology, Clinical trial, IQVIA, BCC, FDA, Sol–gel process, Carcinoma, Food, Pharmaceutical industry

On November 30, 2023, Sol-Gel announced that it had begun Phase 3 testing of SGT-610 for Gorlin syndrome, with the first patient screened.

Key Points: 
  • On November 30, 2023, Sol-Gel announced that it had begun Phase 3 testing of SGT-610 for Gorlin syndrome, with the first patient screened.
  • In addition, TWYNEO increased its broad commercial formulary coverage, with over 6 million additional lives covered between December 2022 and December 2023 per MMIT Analytics.
  • Based on Sol-Gel's financing and adoption of cost-saving measures during 2023, the company continues to maintain its cash runway into the second half of 2025.
  • The decrease in revenues in 2023 resulted mainly from the milestone payment from Galderma related to the FDA approval of Epsolay in 2022.

Quit for Good Signs Global Statement of Support for Tobacco Harm Reduction

Retrieved on: 
Tuesday, November 7, 2023
Knowledge, Ecologist Green Party (Moldova), Harm reduction, Health care, Heated tobacco product, Tobacco, COP10, Public, Nicotine, Good, Health, THR, European Medical Association, Organization, NRT, Smoking, Harm, Environmental disease, Reduction, Herbal cigarette, EMA, FCTC, Patient, WHO, Conference, Public Health England, Society, Annual Review, Public health, Government, Smoke, International Association, Conference of the parties, Smoker, KABAR, EU, Party

Quit For Good is a non-profit organization promoting harm reduction to mitigate the damage caused by cigarette smoke on human health.

Key Points: 
  • Quit For Good is a non-profit organization promoting harm reduction to mitigate the damage caused by cigarette smoke on human health.
  • It is one of the 14 scientific organizations in four continents who support the consensus statement of SCOHRE that the WHO FCTC should not ignore the evidence in support of THR any more.
  • It is also one of the two organizations based in the Philippines that signed the statement, the other being the Harm Reduction Alliance of the Philippines (HARAP).
  • He said providing safer nicotine products to reduce harm for smokers is common sense as smokers are already offered nicotine replacement therapy (NRT) to quit or reduce harm.

BIAL Award in Biomedicine worth 300,000 Euros

Retrieved on: 
Wednesday, April 26, 2023
BioNTech, The New England Journal of Medicine, European Medical Association, The BMJ, European Research Council, Medical journal, COVID-19 vaccine, Perelman School of Medicine at the University of Pennsylvania, Medicina, Jury, University, Nature (journal), Medical Faculty Associates, Messenger, Bangladesh Technical Education Board, Harvard Medical School, Panel, Biology, COVID-19, Council, Saint Andrew's Society, Bial, Medical device, Nursing, Pharmaceutical industry, California Institute of Technology, Biomedicine, Psychology, Neuroscience

TROFA, Portugal, April 26, 2023 /PRNewswire/ -- The third edition of the BIAL Foundation's international award, the BIAL Award in Biomedicine, is now underway, with nominations open until 30 June. With the amount of 300 thousand Euros, this award aims to recognise a work of a broad biomedical nature with exceptional quality and scientific relevance results published within the last ten years.

Key Points: 
  • TROFA, Portugal, April 26, 2023 /PRNewswire/ -- The third edition of the BIAL Foundation's international award, the BIAL Award in Biomedicine, is now underway, with nominations open until 30 June.
  • With the amount of 300 thousand Euros, this award aims to recognise a work of a broad biomedical nature with exceptional quality and scientific relevance results published within the last ten years.
  • Candidates for this international award may be nominated by members of the Jury, members of the Scientific Board of the BIAL Foundation, previous BIAL Award winners, Scientific Societies, Boards or Deans of Medical Faculties, Heads of leading research institutes, and Boards or Heads of prestigious Academies.
  • The BIAL Award in Biomedicine takes place biannually, in odd-numbered years, alternating with the Prémio BIAL de Medicina Clínica.

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Retrieved on: 
Friday, March 10, 2023
Pharmacy benefit management, Nevoid basal-cell carcinoma syndrome, Acquisition, Martin PBM Mariner, EMA, Patient, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Psoriasis, Disease, American Academy of Dermatology, Food, Research, European Medical Association, Breakthrough, Sol–gel process, NDA, Rosacea, Orphan drug, NESS, Prescription, American Academy, Pharmaceutical industry, Cryptocurrency, Dermatology, IQVIA

Investigational compound SGT-610 has the potential to be the first-ever drug for treatment of Gorlin syndrome, if approved.

Key Points: 
  • Investigational compound SGT-610 has the potential to be the first-ever drug for treatment of Gorlin syndrome, if approved.
  • Prescribers reported positive experiences with TWYNEO (launched in April 2022), with the recurring base of prescribers increasing to a high of 82% in Q4 2022, from 66% in Q3 2022.
  • Only 6 months post its June 2022 launch, EPSOLAY captured the #2 branded topical position in rosacea in Q4 2022.
  • EPSOLAY’s recurring base of prescribers increased to 64% of its total prescribers in Q4 2022, from 22% in Q3 2022, showcasing sizeable post-trial adoption.

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Retrieved on: 
Friday, January 27, 2023
Disease, Food, Safety, European Medical Association, Orphan, Nevoid basal-cell carcinoma syndrome, NESS, Mutation, Acquisition, Genetic disorder, Conference call, Dermatology, Orphan drug, NDA, Conference, Drug development, Breakthrough therapy, Patient, BCC, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Syndrome, Psoriasis, PTCH1, EMA, Business Council of Canada (BCC), Autosome, Sol–gel process, Pharmaceutical industry

Sol-Gel broadens its pipeline with this new chemical entity, designated as investigational compound SGT-610, which has the potential to be the first-ever drug for treatment of Gorlin syndrome.

Key Points: 
  • Sol-Gel broadens its pipeline with this new chemical entity, designated as investigational compound SGT-610, which has the potential to be the first-ever drug for treatment of Gorlin syndrome.
  • Sol-Gel expects the transaction to close on or about January 30, 2023, subject to the satisfaction of customary closing conditions.
  • Patidegib has been granted Orphan Drug Designation by the FDA and the EMA as well as Breakthrough Therapy Designation by the FDA.
  • Both FDA and EMA have stated that approval may be supported by a single pivotal Phase 3 study.

A Success Story for the Kozyavkin Program for Cerebral Palsy at Cambridge Medical & Rehabilitation Center

Retrieved on: 
Thursday, August 18, 2022
Trigger, Movement, Press release, Traffic, Long-term care, Muscle, European Medical Association, Physical, United Arab Emirates, INRS, Accident, Najat, Cognition, Behavior, GCC, Adolescence, Group, Trauma, Drug, Communication, Motor disorder, Patient, Quality of life, CARF, Stroke, Kingdom, Massage, Program, Rehabilitation, Her Humble Ministry, CMRC, Nervous system, Spasticity, Child, Infection, Brain damage, Improving Medicare Post-Acute Care Transformation Act of 2014, Seizure, KSA, Neurological disorder, Physician, Occupational therapy, JCI, ABU, CP, EMA, Cerebral palsy, Language, Hospital, Healthcare, Speech

She has undergone four cycles of the program and regular Physiotherapy, Occupational Therapy, and Speech and Language Pathology sessions with great success.

Key Points: 
  • She has undergone four cycles of the program and regular Physiotherapy, Occupational Therapy, and Speech and Language Pathology sessions with great success.
  • Abu Dhabi & Al Ain branches of Cambridge Medical and Rehabilitation Center (CMRC) provide the Intensive Neuro Rehabilitation System (INRS), known as The Kozyavkin Method.
  • The world-class rehabilitation program was created by Dr. Vladimir Kozyavkin over 30 years ago and is accredited by the European Medical Association (EMA.)
  • Dr. Howard Podolsky, Group Chief Executive officer, commented, "Cambridge Medical and Rehabilitation Center is humbled and privileged to provide innovative and ground-breaking care to patients such as Najat.

A Success Story for the Kozyavkin Program for Cerebral Palsy at Cambridge Medical & Rehabilitation Center

Retrieved on: 
Thursday, August 18, 2022
Trigger, Movement, Press release, Traffic, Long-term care, Muscle, European Medical Association, Physical, United Arab Emirates, INRS, Accident, Najat, Cognition, Behavior, GCC, Adolescence, Group, Trauma, Drug, Communication, Motor disorder, Patient, Quality of life, CARF, Stroke, Kingdom, Massage, Program, Rehabilitation, Her Humble Ministry, CMRC, Nervous system, Spasticity, Child, Infection, Brain damage, Improving Medicare Post-Acute Care Transformation Act of 2014, Seizure, KSA, Neurological disorder, Physician, Occupational therapy, JCI, ABU, CP, EMA, Cerebral palsy, Language, Hospital, Healthcare, Speech

She has undergone four cycles of the program and regular Physiotherapy, Occupational Therapy, and Speech and Language Pathology sessions with great success.

Key Points: 
  • She has undergone four cycles of the program and regular Physiotherapy, Occupational Therapy, and Speech and Language Pathology sessions with great success.
  • Abu Dhabi & Al Ain branches of Cambridge Medical and Rehabilitation Center (CMRC) provide the Intensive Neuro Rehabilitation System (INRS), known as The Kozyavkin Method.
  • The world-class rehabilitation program was created by Dr. Vladimir Kozyavkin over 30 years ago and is accredited by the European Medical Association (EMA.)
  • Dr. Howard Podolsky, Group Chief Executive officer, commented, "Cambridge Medical and Rehabilitation Center is humbled and privileged to provide innovative and ground-breaking care to patients such as Najat.

Global Molecular Diagnostics Market Report 2022-2028: Increase in Demand for Point-of-Care and Developments by Market Players & Prevalence of Associated Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 9, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Death, Animal and Plant Health Inspection Service, Global Burden of Disease Study, World Health Organization, Genetic testing, Mortality, Population, Technology, POC, European Medical Writers Association, American Cancer Society, Cancer, Infection, Hospital, Prevalence, Research, Food and Drug Administration, Patient, DNA, COVID-19, Lists of diseases, CVD, Polymerase chain reaction, Institute for Health Metrics and Evaluation, CAGR, WHO, World, Food safety, Software, European Medical Association, Food, Food Safety and Inspection Service, Pharmaceutical industry, Vaccine, Medical device

The "Molecular Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The market growth is mainly attributed to an increase in demand for point-of-care devices, developments by market players, and a rise in the prevalence of associated diseases.
  • However, the increasing prevalence of associated diseases is expected to limit market growth.
  • Molecular diagnostics has wide applications in various indications such as oncology, infectious diseases, genetic testing, cardiac diseases, and immune system disorders.

Gene Editing Global Market Report 2022: A $12.04 Billion Market in 2026, with a CAGR of 17.4% - ResearchAndMarkets.com

Retrieved on: 
Friday, April 15, 2022
Health, Genetics, Lists of diseases, Nature, Technology, User (computing), European Medical Association, COVID-19, WHO, Research, Gene editing, Intention, Bacteria, Human, Fungus, Cell, Growth, Infection, World, Parasitism, Application, Associated Press, Chicago (franchise), Geography, Mosaic, Forecasting, Disease, University, HIV, World Health Organization, Huntington's disease, Virus, Press, Cancer, Medical device, Vaccine, Retail, Pet, EU

The "Gene Editing Global Market Report 2022, By Technology, By End Users, By Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gene Editing Global Market Report 2022, By Technology, By End Users, By Application" report has been added to ResearchAndMarkets.com's offering.
  • Rising infectious diseases acts as one of the major drivers of the gene editing market.
  • Gene editing introduces new genetic material into the cells of living organisms with the intention of treating the diseases.
  • European regulatory framework divided gene therapy into two categories, germline gene therapy, and somatic gene therapy.

Global Gene Editing Market Research Report 2021 Featuring CRISPR, GenScript, Horizon Discovery Group, Integrated DNA Technologies and New England Biolabs - Forecast to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 13, 2021
Infectious Diseases, Health, Genetics, Science, Research, Mosaic, Integration, Agriculture, Associated Press, Bacteria, European Medical Association, Huntington's disease, Intellia Therapeutics, Press, Cell, Infection, Lists of diseases, CRSP, Genome, Gene editing, Human, ZFN, World, Integrated DNA Technologies, Chicago (franchise), Immortalised cell line, COVID-19, Cancer, Fungus, Nature, Cas9, HIV, Parasitism, Intention, Genetic engineering, Research, Biotechnology, Association, Growth, World Health Organization, Disease, DNA, WHO, Genome editing, TALEN, University, NTLA, Food, Virus, National Baptist Convention, USA, Inc., GenScript Biotech, Genetic code, Technology, Vaccine, Antibiotics, Medical device, CRISPR, New England Biolabs, CRISPR, EU

The "Gene Editing Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gene Editing Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the gene editing market are CRISPR, GenScript USA Inc., Horizon Discovery Group plc, Integrated DNA Technologies and New England Biolabs.
  • The gene editing market consists of sales of gene editing technology such as CRISPR/CAS9, zinc finger nucleus, and talens and related services.
  • The gene editing market covered in this report is segmented by technology into CRISPR, TALEN, ZFN.